Sanofi-aventis Says Anticoagulant Clexane Receives Approval In Japan - Quick Facts

Mon. January 28, 2008; Posted: 02:33 AM

(RTTNews) - Monday, Sanofi-aventis (SNY | news | PowerRating | PR Charts ) announced that the anticoagulant Clexane was approved for marketing in Japan by the Ministry of Health, Labour and Welfare for the prevention of venous thromboembolism, or VTE, in patients undergoing orthopaedic surgery of the lower limbs like total hip replacement, total knee replacement and hip fracture surgery.

The company said that venous thromboembolism is a frequent complication among patients hospitalized for orthopaedic surgery.

Commenting on the approval Hanspeter Spek, executive vice-president, Pharmaceutical Operations, Sanofi-aventis said," In Japan, Clexane is expected to greatly contribute to the prevention of venous thromboembolism and fulfill an important medical need for patients undergoing orthopaedic surgery."

For full details on Sanofi-Aventis (SNY) click here. Sanofi-Aventis (SNY) has Short Term PowerRatings of 4. Details on Sanofi-Aventis (SNY) Short Term PowerRatings is available at This Link.

More News: Market Updates | Stock Alerts | All Trading News | Stock Index

Archives

Feedback

Email Article Link

Close X

RELATED SITES

Please call 1-213-955-5858 ext. 1

All analyst commentary provided on TradingMarkets.com is provided for educational purposes only. The analysts and employees or affiliates of TradingMarkets.com may hold positions in the stocks or industries discussed here. This information is NOT a recommendation or solicitation to buy or sell any securities. Your use of this and all information contained on TradingMarkets.com is governed by the Terms and Conditions of Use. Please click the link to view those terms. Follow this link to read our Editorial Policy.